Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + allogeneic G-CSF-mobilized peripheral blood stem cells
- Development stage
- Unknown
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This therapeutic approach involves a combination of the chemotherapy agent gemcitabine and immunotherapy via non-myeloablative allogeneic hematopoietic stem cell transplantation (NST). The procedure utilizes granulocyte colony-stimulating factor-mobilized peripheral blood stem cells (GPBSC) collected from a donor. The goal is to induce a graft-versus-tumor (GVT) effect against unresectable stage III or IV pancreatic cancer. Gemcitabine is used as a conditioning or debulking agent, followed by the infusion of donor GPBSCs to establish a chimeric immune system capable of targeting the malignancy. The non-myeloablative nature of the conditioning regimen allows for the treatment of patients who might not tolerate traditional high-dose myeloablative transplantation.
- Other names
- Non-myeloablative Allogeneic Hematopoietic Stem Cell TransplantationNST in Pancreatic Cancer
02
Targets
RNR (Ribonucleotide reductase)DNA polymerase familyDNA
Beyond the preview
Go deeper on gemcitabine + allogeneic G-CSF-mobilized peripheral blood stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + allogeneic G-CSF-mobilized peripheral blood stem cells.